Physician profile
David E Twardzik
NPI 1457422925
$5,678.57
in general payments reported to CMS, 2019-2025
25 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $188 · 2021: $467 · 2022: $736 · 2023: $1,115 · 2024: $1,343 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,458 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,457.75 |
| Education | $231.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,264.92 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Janssen Biotech, INC. | $1,231.18 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $646.72 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $483.90 | 2019-2025 | Dupixent |
| Incyte Corporation | $300.02 | 2021-2024 | Opzelura |
| Amgen INC. | $205.16 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $202.46 | 2019-2025 | Aklief, Nemluvio |
| Lilly USA, LLC | $198.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Lumenis Be INC | $175.01 | 2025 | M22 |
| Genzyme Corporation | $154.51 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $143.94 | 2023-2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $136.96 | 2019-2025 | |
| Ucb, INC. | $120.43 | 2019-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $99.00 | 2022 | |
| Leo Pharma INC. | $77.81 | 2019-2025 | Anzupgo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $42.00 | 2025 | Sofdra |
| Helsinn Therapeutics (U.S.), INC. | $37.15 | 2019 | |
| Dermira, INC. | $29.71 | 2019 | |
| Celgene Corporation | $25.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.15 | 2024 | Spevigo |
| Organogenesis INC. | $19.38 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $19.38 | 2024 | Ycanth |
| Pfizer INC. | $18.11 | 2019 | |
| Kyowa Kirin, INC. | $15.53 | 2024 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Twardzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.